MCID: CTN007
MIFTS: 68

Cutaneous Leishmaniasis

Categories: Infectious diseases, Skin diseases

Aliases & Classifications for Cutaneous Leishmaniasis

MalaCards integrated aliases for Cutaneous Leishmaniasis:

Name: Cutaneous Leishmaniasis 39 12 15 17
Diffuse Cutaneous Leishmaniasis 12 17 74
Asian Desert Cutaneous Leishmaniasis 12 74
Leishmaniasis, Cutaneous 45 74
Ethiopian Cutaneous Leishmaniasis 74
Leishmaniasis Diffuse Cutaneous 56
Leishmaniasis Cutaneous 56
Leproid Leishmaniasis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:9111
MeSH 45 D016773
NCIt 51 C34768
ICD10 34 B55.1

Summaries for Cutaneous Leishmaniasis

Disease Ontology : 12 A leishmaniasis that involves skin infection caused by Leishmania species, resulting in one or more cutaneous lesions.

MalaCards based summary : Cutaneous Leishmaniasis, also known as diffuse cutaneous leishmaniasis, is related to leishmaniasis and acquired immunodeficiency syndrome. An important gene associated with Cutaneous Leishmaniasis is IFNG (Interferon Gamma), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Miconazole and Miltefosine have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and testes, and related phenotypes are hematopoietic system and growth/size/body region

Wikipedia : 77 Cutaneous leishmaniasis (also known as oriental sore, tropical sore, chiclero ulcer, chiclero''s ulcer,... more...

Related Diseases for Cutaneous Leishmaniasis

Diseases related to Cutaneous Leishmaniasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 305)
# Related Disease Score Top Affiliating Genes
1 leishmaniasis 31.3 IFNG IL10 IL13 IL4 IL5 LMLN
2 acquired immunodeficiency syndrome 30.9 IFNG IL10 TNF
3 human immunodeficiency virus infectious disease 30.7 IFNG IL10 TNF
4 sporotrichosis 30.5 IFNG IL10
5 african tick-bite fever 30.4 IFNG IL13
6 chagas disease 30.4 IFNG IL10 TLR2 TLR4 TNF
7 leprosy 3 30.3 IFNG IL10 SLC11A1 TLR2 TNF
8 dermatitis 30.3 IFNG IL13 IL4 IL5
9 meningitis 30.2 IFNG IL10 TLR2 TNF
10 cytokine deficiency 30.1 IL13 IL5
11 uveitis 30.0 IFNG IL10 IL4 TNF
12 sezary's disease 30.0 IFNG IL4 IL5
13 lepromatous leprosy 30.0 IFNG IL10 TLR2 TNF
14 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 29.9 FOXP3 IFNG IL10 IL4
15 trypanosomiasis 29.8 IFNG IL10 IL4 TLR2 TNF
16 bacterial infectious disease 29.8 IFNG IL10 SLC11A1 TLR2 TLR4 TNF
17 lymphadenitis 29.8 IFNG IL10 SLC11A1 TLR4 TNF
18 melioidosis 29.8 IFNG IL10 TLR2 TLR4 TNF
19 pulmonary tuberculosis 29.6 IFNG IL10 IL4 SLC11A1 TLR2 TNF
20 brucellosis 29.6 IFNG IL10 IL4 SLC11A1 TLR4 TNF
21 folliculitis 29.6 IFNG IL4 IL5
22 multiple sclerosis 29.5 FOXP3 IFNG IL10 IL4 TNF
23 contact dermatitis 29.4 IFNG IL10 IL4 IL5 TNF
24 rheumatoid arthritis 29.2 FOXP3 IFNG IL10 IL4 SLC11A1 TLR2
25 visceral leishmaniasis 29.0 FOXP3 IFNG IL10 IL4 LMLN PGD
26 malaria 28.2 FOXP3 G6PD IFNG IL10 IL13 IL4
27 mucocutaneous leishmaniasis 12.0
28 b-cell growth factor 10.5 IFNG IL4
29 retinitis pigmentosa 22 10.5 IL10 IL4
30 trichosporonosis 10.5 IFNG TNF
31 choroiditis 10.5 IL10 TNF
32 autoimmune myocarditis 10.5 IFNG TNF
33 staphylococcal toxic shock syndrome 10.5 IFNG TNF
34 chronic beryllium disease 10.5 IFNG TNF
35 transient hypogammaglobulinemia 10.5 IL10 TNF
36 multifocal choroiditis 10.5 IL10 TNF
37 punctate inner choroidopathy 10.5 IL10 TNF
38 variola major 10.5 IFNG TLR4
39 neurosyphilis 10.5 IL10 TLR2
40 pouchitis 10.5 IL10 TLR4
41 ascaridiasis 10.5 IL10 IL13
42 prosthetic joint infection 10.5 TLR2 TLR4
43 persistent polyclonal b-cell lymphocytosis 10.4 FCER2 IL4
44 6-phosphogluconate dehydrogenase deficiency 10.4 G6PD PGD
45 dengue hemorrhagic fever 10.4 IFNG IL10 TNF
46 osteomyelitis 10.4 IFNG IL10 TNF
47 hepatitis a 10.4 IFNG IL10 TNF
48 chronic mucocutaneous candidiasis 10.4 IFNG IL10 TNF
49 rheumatic disease 10.4 IFNG IL10 TNF
50 demyelinating disease 10.4 IFNG IL10 TNF

Graphical network of the top 20 diseases related to Cutaneous Leishmaniasis:



Diseases related to Cutaneous Leishmaniasis

Symptoms & Phenotypes for Cutaneous Leishmaniasis

MGI Mouse Phenotypes related to Cutaneous Leishmaniasis:

47 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.31 FCER2 FOXP3 G6PD GPI IFNG IL10
2 growth/size/body region MP:0005378 10.29 FOXP3 G6PD GPI IFNG IL10 IL13
3 cellular MP:0005384 10.28 FCER2 FOXP3 G6PD IFNG IL10 IL13
4 digestive/alimentary MP:0005381 10.26 FCER2 FOXP3 IFNG IL10 IL13 IL4
5 homeostasis/metabolism MP:0005376 10.26 FCER2 FOXP3 G6PD GPI IFNG IL10
6 immune system MP:0005387 10.23 FCER2 FOXP3 GPI IFNG IL10 IL13
7 cardiovascular system MP:0005385 10.2 FOXP3 G6PD GPI IFNG IL10 MPI
8 mortality/aging MP:0010768 10.18 FCER2 FOXP3 G6PD GPI IFNG IL10
9 liver/biliary system MP:0005370 10.06 FOXP3 GPI IFNG IL10 IL4 IL5
10 integument MP:0010771 10.03 FOXP3 IFNG IL10 IL13 IL4 TLR2
11 neoplasm MP:0002006 9.87 IFNG IL10 IL5 SLC11A1 TLR2 TLR4
12 no phenotypic analysis MP:0003012 9.8 FOXP3 GPI IFNG IL10 IL13 IL4
13 reproductive system MP:0005389 9.76 FOXP3 IFNG IL10 IL13 IL4 IL5
14 respiratory system MP:0005388 9.65 FOXP3 GPI IFNG IL10 IL13 IL4
15 skeleton MP:0005390 9.28 IFNG IL10 IL13 IL4 MPI PGD

Drugs & Therapeutics for Cutaneous Leishmaniasis

Drugs for Cutaneous Leishmaniasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 71)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
2
Miltefosine Approved, Investigational Phase 4,Phase 3,Phase 2 58066-85-6 3600
3
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3 137-58-6 3676
4
meglumine antimoniate Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 133-51-7
5 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
6 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
7 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
8 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1
9 Anthelmintics Phase 4,Phase 2,Not Applicable
10 Antimony Sodium Gluconate Phase 4,Phase 2,Not Applicable
11 Anesthetics Phase 4
12
Pentoxifylline Approved, Investigational Phase 2, Phase 3,Phase 3 6493-05-6 4740
13
Paromomycin Approved, Investigational Phase 3,Phase 2,Early Phase 1,Not Applicable 7542-37-2, 1263-89-4 165580
14
Imiquimod Approved, Investigational Phase 3,Phase 2 99011-02-6 57469
15
Pentamidine Approved, Investigational Phase 2, Phase 3 100-33-4 4735
16
carbamide peroxide Approved Phase 2, Phase 3 124-43-6
17
Aluminum sulfate Approved Phase 2, Phase 3,Phase 3,Phase 1 10043-01-3
18
Nitric Oxide Approved Phase 3 10102-43-9 145068
19
Sargramostim Approved, Investigational Phase 3,Phase 2 123774-72-1, 83869-56-1
20
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
21
Azithromycin Approved Phase 2, Phase 3 83905-01-5 447043 55185
22 Phosphodiesterase Inhibitors Phase 2, Phase 3,Phase 3
23 Radiation-Protective Agents Phase 2, Phase 3,Phase 3
24 Platelet Aggregation Inhibitors Phase 2, Phase 3,Phase 3
25 Protective Agents Phase 2, Phase 3,Phase 3,Not Applicable
26 Antioxidants Phase 2, Phase 3,Phase 3,Not Applicable
27 Vasodilator Agents Phase 2, Phase 3,Phase 3
28 Free Radical Scavengers Phase 2, Phase 3,Phase 3,Not Applicable
29 Adjuvants, Immunologic Phase 2, Phase 3,Phase 3,Phase 1
30 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
31 Gentamicins Phase 3,Phase 2,Not Applicable
32 Antibiotics, Antitubercular Phase 3,Phase 2
33 interferons Phase 3,Phase 2
34 Interferon Inducers Phase 3,Phase 2
35 Immunologic Factors Phase 3,Phase 2,Phase 1
36 Vaccines Phase 2, Phase 3,Phase 3,Phase 1
37 Neurotransmitter Agents Phase 3,Phase 2
38 Anti-Asthmatic Agents Phase 3
39 Autonomic Agents Phase 3
40 Peripheral Nervous System Agents Phase 3
41 Endothelium-Dependent Relaxing Factors Phase 3
42 Bronchodilator Agents Phase 3
43 Respiratory System Agents Phase 3
44 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
45 Cytochrome P-450 CYP2C9 Inhibitors Phase 3
46 Hormone Antagonists Phase 3
47 Cytochrome P-450 CYP2C19 Inhibitors Phase 3
48 Cytochrome P-450 Enzyme Inhibitors Phase 3
49 Hormones Phase 3
50 Steroid Synthesis Inhibitors Phase 3

Interventional clinical trials:

(show top 50) (show all 78)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Low-Dose Pentavalent Antimony for Treatment of Cutaneous Leishmaniasis Completed NCT00317980 Phase 4 Meglumine antimoniate;Meglumine antimoniate
2 Low-dose Pentavalent Antimony Treatment of Cutaneous Leishmaniasis in Old Age Patients Completed NCT00818818 Phase 4 Meglumine antimoniate
3 Pharmacokinetics of Miltefosine in Children and Adults Completed NCT01462500 Phase 4 Miltefosine
4 Efficacy of Radio-frequency Induced Heat (RFH)Therapy in Treatment of Cutaneous Leishmaniasis in India Completed NCT01661296 Phase 4 Sodium stibogluconate
5 Oral Miltefosine for the Treatment of Pediatric Cutaneous Leishmaniasis in Colombia Unknown status NCT00487253 Phase 3 Miltefosine;Meglumine antimoniate
6 Antimony Plus Pentoxifylline in Cutaneous Leishmaniasis Completed NCT01381055 Phase 2, Phase 3 Pentoxifylline;Placebo
7 Add-on Study of Pentoxifylline in Cutaneous Leishmaniasis Completed NCT01464242 Phase 2, Phase 3 Meglumine antimonate;Placebo;Pentoxifylline
8 Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis Completed NCT01301924 Phase 2, Phase 3 Meglumine antimoniate
9 Phase 3 Study to Evaluate WR 279,396 vs. Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia) Completed NCT00606580 Phase 3 WR 279,396 topical cream;Paromomycin Alone topical cream;Vehicle placebo cream
10 Efficacy and Safety of Miltefosine or Thermotherapy for Cutaneous Leishmaniasis in Colombia. Completed NCT00471705 Phase 3 Miltefosine;Glucantime®
11 Imiquimod Plus Antimony Immunochemotherapy for Cutaneous Leishmaniasis Completed NCT00257530 Phase 3 Imiquimod
12 Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama Completed NCT01790659 Phase 3 WR 279,396;Paromomycin
13 Efficacy Trial on Oral Miltefosine in Comparison With Glucantime in the Treatment of ACL Caused by L. Tropica Completed NCT00351520 Phase 3 Miltefose
14 Rationale for New Topical Anthroponotic Cutaneous Leishmaniasis (ACL) Treatment in Kabul Completed NCT00947362 Phase 2, Phase 3 DAC N-055;saline
15 Topical Paromomycin for Cutaneous Leishmaniasis in Bolivia Completed NCT03096457 Phase 2, Phase 3 Paromomycin Sulfate;Pentamidine Isethionate
16 Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With no Response to Leishmanin Completed NCT00429715 Phase 2, Phase 3
17 Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With Positive Response to Leishmanin (LST>0) Completed NCT00429780 Phase 2, Phase 3
18 Clinical Trial for the Treatment of Diabetic Foot Ulcers Using a Nitric Oxide Releasing Patch: PATHON Completed NCT00428727 Phase 3 Controlled nitric oxide releasing patch;placebo patch
19 Miltefosine and GM-CSF in Cutaneous Leishmaniasis Not yet recruiting NCT03023111 Phase 3 Sbv;Miltefosine plus placebo;Miltefosine plus GM-CSF
20 Oral Miltefosine Plus Topical Paromomycin In American Cutaneous Leishmaniasis Not yet recruiting NCT03829917 Phase 2, Phase 3 Miltefosine and Paromomycin;miltefosine;paromomycin
21 High Dose Fluconazole in Cutaneous Leishmaniasis in Bahia and Manaus Terminated NCT01953744 Phase 3 Fluconazole;Meglumine Antimoniate
22 Safety and Efficacy of Azithromycin to Treat Cutaneous Leishmaniasis Terminated NCT00682656 Phase 2, Phase 3 Glucantime®;Zithromax ®
23 Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis Terminated NCT00317629 Phase 3 controlled nitric oxide releasing patch;meglumine antimoniate
24 Effectiveness, Safety and Feasibility of HECT-CL, in Quetta, Pakistan Terminated NCT03208543 Phase 3
25 Study of the Efficacy of Daylight Activated Photodynamic Therapy in the Treatment of Cutaneous Leishmaniasis Unknown status NCT00840359 Phase 2
26 Short Course of Miltefosine and Antimony to Treat Cutaneous Leishmaniasis in Bolivia Unknown status NCT00537953 Phase 2 Miltefosine , meglumine antimoniate
27 Efficacy and Safety of Pentamidine (7mg/kg) for Patients With Cutaneous Leishmaniasis Caused by L. Guyanensis Completed NCT02919605 Phase 2 Single dose of Pentamidine;Two doses of Pentamidine;Three doses of Pentamidine
28 Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old World Completed NCT00703924 Phase 2 WR 279,396;Placebo
29 WR 279,396 for the Treatment of Cutaneous Leishmaniasis Completed NCT01988909 Phase 2 WR 279,396
30 Topical 3% Amphotericin B Cream for the Treatment of Cutaneous Leishmaniasis in Colombia Completed NCT01845727 Phase 1, Phase 2 Topical Amphotericin B at 3%
31 Trial of Miltefosine in Cutaneous Leishmaniasis (Brazil) Completed NCT00600548 Phase 2 Miltefosine.;Meglumine antimoniate.;Miltefosine.;Meglumine antimoniate.
32 Reduced Doses of Antimony Plus Ranulocyte Monocyte Colony Stimulating Factor (GM-CSF) for Cutaneous Leishmaniasis Completed NCT00973128 Phase 2 GMCSF plus Antimony reduced dose;Meglumine antimoniate
33 Oral Miltefosine Plus Topical Imiquimod to Treat Cutaneous Leishmaniasis Completed NCT01380314 Phase 2 Miltefosine + Imiquimod;Miltefosine 150 mg x day + Placebo
34 Miltefosine to Treat Cutaneous Leishmaniasis in Bolivia Completed NCT00233545 Phase 2 miltefosine;antimony
35 Local Heat Therapy Versus Sodium Stibogluconate for the Treatment of Cutaneous Leishmaniasis Completed NCT00884377 Phase 2 Sodium stibogluconate (Pentostam)
36 A Study of the Efficacy and Safety of the LEISH-F2 + MPL-SE Vaccine for Treatment of Cutaneous Leishmaniasis Completed NCT01011309 Phase 2 Sodium stibogluconate
37 A Study to Evaluate the Efficacy and Tolerance of WR279,396 for Old World Cutaneous Leishmaniasis Completed NCT01536795 Phase 2 WR279 396 with Tegaderm Dressing;WR 279, 396 with Gauze and Tape Dressing
38 Fourth-generation Immucillin Derivative DI4G Associated Therapy in Cutaneous Leishmaniasis Completed NCT03294161 Phase 2 Immucillin DI4G;Meglumine antimoniate
39 Intralesional Antimony for Bolivian Cutaneous Leishmaniasis Completed NCT01300975 Phase 2 pentavalent antimony;placebo cream
40 Pharmacokinetics, Safety, and Efficacy Trial of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream for the Treatment of Cutaneous Leishmaniasis in Panama Completed NCT01083576 Phase 2 WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream);Paromomycin Alone Cream (15% paromomycin topical cream)
41 Safety, Efficacy and Pharmacokinetics (PK) Study of WR 279,396 Versus Paromomycin for Treatment of Cutaneous Leishmaniasis (Peru-PK) Completed NCT01032382 Phase 2 WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream);Paromomycin Alone Cream (15% paromomycin topical cream)
42 Rationales for Wound Care Management in Old World Cutaneous Leishmaniasis Patients Completed NCT00996463 Phase 2 Sodium Stibogluconate;DAC N-055
43 Allopurinol, Glucantime, or Allopurinol/Glucantime for Cutaneous Leishmaniasis in Brazil Completed NCT00004755 Phase 2 allopurinol;glucantime
44 Miltefosine Plus IL Pentamidine for Bolivian CL Completed NCT03445897 Phase 2 miltefosine plus intralesional pentamidine
45 Miltefosine to Treat Mucocutaneous Leishmaniasis Completed NCT01050907 Phase 2 miltefosine
46 Safety, False-Positive Reactions and Sensitizing Properties of Leishmania Tropica Skin Test Antigen Completed NCT00633009 Phase 2
47 Study to Evaluate the Leish-111f + MPL-SE Vaccine in Healthy Adults Not Previously Exposed to Leishmania Parasite Completed NCT00121862 Phase 2
48 Sodium Stibogluconate Treatment of Leishmaniasis Completed NCT00662012 Phase 2 Sodium Stibogluconate (SSG)
49 Topical Liposomal Amphotericin B Gel Treatment for Cutaneous Leishmaniasis Recruiting NCT02656797 Phase 2 Topical Amphotericin-B 0.4% liposomal gel
50 Thermotherapy + a Short Course of Miltefosine for the Treatment of Uncomplicated Cutaneous Leishmaniasis in the New World¨ Active, not recruiting NCT02687971 Phase 2 Miltefosine

Search NIH Clinical Center for Cutaneous Leishmaniasis

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: leishmaniasis, cutaneous

Genetic Tests for Cutaneous Leishmaniasis

Anatomical Context for Cutaneous Leishmaniasis

MalaCards organs/tissues related to Cutaneous Leishmaniasis:

42
Skin, T Cells, Testes, Monocytes, Lung, Neutrophil, B Cells

Publications for Cutaneous Leishmaniasis

Articles related to Cutaneous Leishmaniasis:

(show top 50) (show all 3073)
# Title Authors Year
1
Anti-tumour necrosis factor-associated cutaneous leishmaniasis: a single-institution experience. ( 30659588 )
2019
2
Resolution of Cutaneous Leishmaniasis and Persistence of Leishmania major in the Absence of Arginase 1. ( 30665936 )
2019
3
How cutaneous leishmaniasis and treatment impacts in the patients' lives: A cross-sectional study. ( 30682151 )
2019
4
The increase in neglected cutaneous leishmaniasis in Gaziantep province of Turkey after mass human migration. ( 30710533 )
2019
5
Cutaneous Leishmaniasis: Updates in Diagnosis and Management. ( 30712756 )
2019
6
Isolated conjunctival involvement in a case of cutaneous leishmaniasis. ( 30722746 )
2019
7
Detection, genotyping, and phylogenetic analysis of Leishmania isolates collected from infected Jordanian residents and Syrian refugees who suffered from cutaneous leishmaniasis. ( 30729301 )
2019
8
Intralesional sodium stibogluconate under inhaled anesthesia for the treatment of cutaneous leishmaniasis in children: A retrospective cohort. ( 30731176 )
2019
9
Protection induced by Leishmania Major antigens and the imiquimod adjuvant encapsulated on liposomes in experimental cutaneous leishmaniasis. ( 30738195 )
2019
10
Host's immune response in unresponsive and responsive patients with anthroponotic cutaneous leishmaniasis treated by meglumine antimoniate: A case-control study of Th1 and Th2 pathways. ( 30771740 )
2019
11
Rhinophyma-Like Cutaneous Leishmaniasis due to Leishmania aethiopica Treated Successfully with Liposomal Amphotericin B. ( 30774067 )
2019
12
Chitosan-based biocompatible dressing for treatment of recalcitrant lesions of cutaneous leishmaniasis: A pilot clinical study. ( 30785121 )
2019
13
Leishmania spp. Infection Rate and Feeding Patterns of Sand Flies (Diptera: Psychodidae) from a Hyperendemic Cutaneous Leishmaniasis Community in Panamá. ( 30793681 )
2019
14
Cutaneous leishmaniasis and co-morbid major depressive disorder: A systematic review with burden estimates. ( 30802261 )
2019
15
Thirty years of cutaneous leishmaniasis in Tadla-Azilal focus, Morocco. ( 30805563 )
2019
16
Histological and immunological differences between zoonotic cutaneous leishmaniasis due to Leishmania major and sporadic cutaneous leishmaniasis due to Leishmania infantum. ( 30810524 )
2019
17
Anti-leishmanial activity of a topical miltefosine gel in experimental models of New World cutaneous leishmaniasis. ( 30815688 )
2019
18
Diel periodicity and visual cues guide oviposition behavior in Phlebotomus papatasi, vector of old-world cutaneous leishmaniasis. ( 30835733 )
2019
19
Disseminated Cutaneous Leishmaniasis in a Patient Infected by Leishmania panamensis. ( 30843505 )
2019
20
Host and parasite responses in human diffuse cutaneous leishmaniasis caused by L. amazonensis. ( 30845223 )
2019
21
Imported cutaneous leishmaniasis: a 13-year experience of a Polish tertiary center. ( 30858788 )
2019
22
Alterations in monocyte subsets and cytokine production after TLR activation in American Cutaneous Leishmaniasis. ( 30870579 )
2019
23
Performance of immunohistochemistry as a useful tool for the diagnosis of cutaneous leishmaniasis in Panama, Central America. ( 30885795 )
2019
24
10-Year Trends in Epidemiology, Diagnosis, and Treatment of Cutaneous Leishmaniasis in Hamadan Province, West of Iran (2007-2016). ( 30891438 )
2019
25
The activity of encapsulated meglumine antimoniate in stearylamine-bearing liposomes against cutaneous leishmaniasis in BALB/c mice. ( 30898544 )
2019
26
Expansion of urban cutaneous leishmaniasis into rural areas of southeastern Iran: Clinical, epidemiological and phylogenetic profiles explored using 7SL high resolution melting-PCR analysis. ( 30912874 )
2019
27
Novel benzoxaborole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis. ( 30922847 )
2019
28
Cutaneous Leishmaniasis caused by L. Infantum. ( 30925973 )
2019
29
The epidemiology of cutaneous leishmaniasis in Golestan Province, Iran: A cross-sectional study of 8-years. ( 30937404 )
2019
30
A Case of Cutaneous Leishmaniasis Caused by Leishmania infantum ( 30938136 )
2019
31
Prevalence of Cutaneous Leishmaniasis in Western Highlands in Yemen. ( 30941183 )
2019
32
Binational burden of American cutaneous leishmaniasis in Oiapoque, Amapá State, Brazil, bordering French Guiana. ( 30942256 )
2019
33
The therapeutic effect of ozonated olive oil plus glucantime on human cutaneous leishmaniasis. ( 30944704 )
2019
34
Study of the efficacy of N-methyl glucamine antimoniate (SbV) associated with photodynamic therapy using liposomal chloroaluminium phthalocyanine in the treatment of cutaneous leishmaniasis caused by Leishmania (L.) amazonensis in C57BL6 mice. ( 30951865 )
2019
35
Prevalence of Leishmania species among patients with cutaneous leishmaniasis in Qassim province of Saudi Arabia. ( 30953481 )
2019
36
Level of circulating steroid hormones in malaria and cutaneous leishmaniasis: a case control study. ( 30956446 )
2019
37
Epidemiological features of a recent zoonotic cutaneous leishmaniasis outbreak in Zagora province, southern Morocco. ( 30964864 )
2019
38
Cutaneous leishmaniasis: an evolving disease with ancient roots. ( 30968403 )
2019
39
Cutaneous leishmaniasis among Syrian refugees in Jordan. ( 30974096 )
2019
40
Identification of priority areas for surveillance of cutaneous leishmaniasis using spatial analysis approaches in Southeastern Brazil. ( 30975100 )
2019
41
Experimental Cutaneous Leishmaniasis: Mouse Models for Resolution of Inflammation Versus Chronicity of Disease. ( 30980313 )
2019
42
Chronic Relapsing Cutaneous Leishmaniasis in an Elderly Female: A Rare Clinical Presentation from a Nonendemic Area. ( 30984593 )
2019
43
An outbreak of cutaneous leishmaniasis among a displaced population in North Sudan: Review of cases. ( 30984672 )
2019
44
The topical treatment of old world cutaneous leishmaniasis with gentian violet along with cryotherapy: a pilot single-blind randomized controlled clinical trial. ( 30994790 )
2019
45
First report of treatment failure in a patient with cutaneous leishmaniasis infected by Leishmania (Viannia) naiffi carrying Leishmania RNA virus: a fortuitous combination? ( 30994803 )
2019
46
Activated cytotoxic T cells within zoonotic cutaneous leishmaniasis lesions. ( 30997749 )
2019
47
Efficacy of miltefosine compared with glucantime for the treatment of cutaneous leishmaniasis: a systematic review and meta-analysis. ( 30999735 )
2019
48
Comparing the Efficacy of Oral Chloroquine versus Oral Tetracycline in the Treatment of Cutaneous Leishmaniasis. ( 31036105 )
2019
49
Leishmania (Viannia) braziliensis type 2 as probable etiological agent of canine cutaneous leishmaniasis in Brazilian Amazon. ( 31039202 )
2019
50
The Effect of Pentavalent Antimonial Compounds used in the Treatment of Cutaneous Leishmaniasis on Hemogram and Biochemical Parameters. ( 31039622 )
2019

Variations for Cutaneous Leishmaniasis

Expression for Cutaneous Leishmaniasis

LifeMap Discovery
Genes differentially expressed in tissues of Cutaneous Leishmaniasis patients vs. healthy controls: 35 (show top 50) (show all 174)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 CXCL9 chemokine (C-X-C motif) ligand 9 Skin + 6.42 0.000
2 CXCL10 chemokine (C-X-C motif) ligand 10 Skin + 6.16 0.000
3 IDO1 indoleamine 2,3-dioxygenase 1 Skin + 5.97 0.000
4 GZMB granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1) Skin + 5.88 0.000
5 GBP5 guanylate binding protein 5 Skin + 5.82 0.000
6 PIP prolactin-induced protein Skin - 5.80 0.000
7 GNLY granulysin Skin + 5.77 0.000
8 MMP1 matrix metallopeptidase 1 Skin + 5.47 0.000
9 DCD dermcidin Skin - 5.36 0.000
10 GZMA granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3) Skin + 5.30 0.000
11 SCGB1D2 secretoglobin, family 1D, member 2 Skin - 5.14 0.000
12 CCL8 chemokine (C-C motif) ligand 8 Skin + 5.01 0.000
13 NKG7 natural killer cell granule protein 7 Skin + 4.99 0.000
14 GZMK granzyme K (granzyme 3; tryptase II) Skin + 4.89 0.000
15 SCGB2A2 secretoglobin, family 2A, member 2 Skin - 4.87 0.000
16 IGLL1 immunoglobulin lambda-like polypeptide 1 Skin + 4.82 0.000
17 CCL5 chemokine (C-C motif) ligand 5 Skin + 4.78 0.000
18 MMP3 matrix metallopeptidase 3 Skin + 4.69 0.000
19 CCL3L3 chemokine (C-C motif) ligand 3-like 3 Skin + 4.67 0.000
20 UBD ubiquitin D Skin + 4.67 0.000
21 ADAMDEC1 ADAM-like, decysin 1 Skin + 4.65 0.000
22 EPSTI1 epithelial stromal interaction 1 (breast) Skin + 4.53 0.000
23 JCHAIN joining chain of multimeric IgA and IgM Skin + 4.53 0.000
24 C5orf46 chromosome 5 open reading frame 46 Skin - 4.53 0.000
25 C1QB complement component 1, q subcomponent, B chain Skin + 4.51 0.000
26 GZMH granzyme H (cathepsin G-like 2, protein h-CCPX) Skin + 4.48 0.000
27 GBP1 guanylate binding protein 1, interferon-inducible Skin + 4.45 0.000
28 CCL4L1 chemokine (C-C motif) ligand 4-like 1 Skin + 4.44 0.000
29 MED27 mediator complex subunit 27 Skin - 4.31 0.000
30 FCER1G Fc fragment of IgE, high affinity I, receptor for; gamma polypeptide Skin + 4.29 0.000
31 KIR2DL3 killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 3 Skin + 4.27 0.000
32 SERPINA12 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 12 Skin - 4.25 0.000
33 GBP4 guanylate binding protein 4 Skin + 4.23 0.000
34 CD8A CD8a molecule Skin + 4.23 0.000
35 TDO2 tryptophan 2,3-dioxygenase Skin + 4.19 0.000
36 FCGR1A Fc fragment of IgG, high affinity Ia, receptor (CD64) Skin + 4.17 0.000
37 CXCL8 chemokine (C-X-C motif) ligand 8 Skin + 4.13 0.000
38 KRT27 keratin 27, type I Skin - 4.13 0.000
39 DAPL1 death associated protein-like 1 Skin - 4.10 0.000
40 LYZ lysozyme Skin + 4.10 0.000
41 THRSP thyroid hormone responsive Skin - 4.06 0.000
42 CHP2 calcineurin-like EF-hand protein 2 Skin - 4.03 0.000
43 PRF1 perforin 1 (pore forming protein) Skin + 4.03 0.000
44 LAG3 lymphocyte-activation gene 3 Skin + 3.99 0.000
45 CYBB cytochrome b-245, beta polypeptide Skin + 3.98 0.000
46 WARS tryptophanyl-tRNA synthetase Skin + 3.98 0.000
47 CD3D CD3d molecule, delta (CD3-TCR complex) Skin + 3.97 0.000
48 IL18BP interleukin 18 binding protein Skin + 3.96 0.000
49 SNX10 sorting nexin 10 Skin + 3.96 0.000
50 SERPINA1 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 Skin + 3.95 0.000
Search GEO for disease gene expression data for Cutaneous Leishmaniasis.

Pathways for Cutaneous Leishmaniasis

Pathways related to Cutaneous Leishmaniasis according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.02 FCER2 GPI IFNG IL10 IL13 IL4
2
Show member pathways
13.65 FCER2 IFNG IL10 IL13 IL4 IL5
3
Show member pathways
13.39 IL10 IL13 IL4 IL5 TLR2 TLR4
4
Show member pathways
13.35 FCER2 IFNG IL10 IL13 IL4 IL5
5
Show member pathways
13.18 FCER2 IFNG IL4 TLR2 TLR4 TNF
6
Show member pathways
12.88 FOXP3 GZMB IFNG IL10 IL13 IL4
7
Show member pathways
12.59 IFNG IL10 IL4 IL5 TNF
8
Show member pathways
12.55 IL13 IL4 IL5 TNF
9 12.54 FOXP3 GZMB IFNG IL10 IL4 TLR2
10
Show member pathways
12.49 GZMB IFNG IL4 TNF
11
Show member pathways
12.43 IFNG IL10 IL13 IL4 IL5
12
Show member pathways
12.36 IFNG IL13 IL4 IL5 TLR2 TNF
13
Show member pathways
12.35 FOXP3 IFNG IL10 IL13 IL4 IL5
14
Show member pathways
12.29 IFNG IL10 IL13 IL4 IL5 TNF
15 12.28 IFNG IL10 TLR2 TLR4 TNF
16
Show member pathways
12.27 IFNG IL10 IL4 TLR2 TLR4 TNF
17
Show member pathways
12.23 IFNG IL4 TLR2 TLR4 TNF
18 12.2 IFNG TLR2 TLR4 TNF
19
Show member pathways
12.1 IFNG IL10 TLR2 TLR4 TNF
20
Show member pathways
12.09 IFNG IL10 IL13 IL4 IL5
21
Show member pathways
12.05 IL13 IL5 TLR2 TLR4
22 12.04 IFNG IL10 IL4 IL5 TNF
23 12.03 IFNG IL4 TLR4 TNF
24
Show member pathways
12.03 IFNG IL13 IL4 TLR2 TLR4 TNF
25 12.02 FCER2 IL10 IL13 IL4 TNF
26
Show member pathways
11.94 GZMB IFNG IL4
27 11.94 IFNG IL10 TLR2 TLR4 TNF
28 11.93 FCER2 IL4 IL5 TNF
29 11.9 IFNG TLR2 TLR4 TNF
30 11.85 IFNG IL13 IL4 IL5
31 11.81 FCER2 TLR2 TLR4
32
Show member pathways
11.79 FOXP3 IFNG IL4 IL5 TNF
33 11.76 IL10 TLR4 TNF
34 11.74 IFNG IL10 TNF
35 11.74 IFNG IL10 IL13 IL4 TNF
36 11.72 FCER2 IL10 IL4 IL5
37 11.72 IL13 IL4 IL5 TNF
38
Show member pathways
11.68 G6PD GPI PGD
39
Show member pathways
11.65 GZMB IFNG TNF
40 11.6 TLR2 TLR4 TNF
41 11.57 IFNG TLR2 TLR4 TNF
42 11.52 FCER2 IL10 IL13 IL4 TNF
43 11.49 IFNG IL10 TLR2 TLR4 TNF
44 11.42 IFNG IL10 TNF
45 11.4 FOXP3 IFNG IL10 IL13 IL4 IL5
46 11.4 GZMB IFNG IL10 IL13 IL4 IL5
47 11.39 IL10 TLR4 TNF
48 11.36 IFNG IL4 IL5
49 11.27 IFNG IL13 IL4 IL5 TNF
50 11.26 IL10 IL13 IL4 IL5 TNF

GO Terms for Cutaneous Leishmaniasis

Cellular components related to Cutaneous Leishmaniasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.23 FCER2 GPI IFNG IL10 IL13 IL4

Biological processes related to Cutaneous Leishmaniasis according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Name GO ID Score Top Affiliating Genes
1 defense response to bacterium GO:0042742 9.99 IL10 SLC11A1 TLR4 TNF
2 cytokine-mediated signaling pathway GO:0019221 9.91 FCER2 IL10 IL13 IL4 IL5 TNF
3 positive regulation of DNA-binding transcription factor activity GO:0051091 9.9 IL10 IL5 TNF
4 response to virus GO:0009615 9.9 FOXP3 IFNG TNF
5 positive regulation of inflammatory response GO:0050729 9.87 TLR2 TLR4 TNF
6 regulation of signaling receptor activity GO:0010469 9.87 GPI IFNG IL10 IL13 IL4 IL5
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.86 IFNG IL13 IL4
8 positive regulation of interleukin-6 production GO:0032755 9.85 TLR2 TLR4 TNF
9 humoral immune response GO:0006959 9.85 GPI IFNG TNF
10 response to lipopolysaccharide GO:0032496 9.85 IL10 IL13 SLC11A1 TLR2 TLR4
11 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.84 TLR2 TLR4 TNF
12 negative regulation of tumor necrosis factor production GO:0032720 9.83 FOXP3 IL10 TLR4
13 positive regulation of interferon-gamma production GO:0032729 9.83 SLC11A1 TLR4 TNF
14 positive regulation of nitric oxide biosynthetic process GO:0045429 9.81 IFNG TLR4 TNF
15 negative regulation of endothelial cell apoptotic process GO:2000352 9.78 IL10 IL13 IL4
16 lipopolysaccharide-mediated signaling pathway GO:0031663 9.77 TLR2 TLR4 TNF
17 negative regulation of interferon-gamma production GO:0032689 9.77 FOXP3 IL10 TLR4
18 positive regulation of interleukin-8 production GO:0032757 9.76 TLR2 TLR4 TNF
19 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.72 IFNG TNF
20 regulation of regulatory T cell differentiation GO:0045589 9.72 FOXP3 IFNG
21 negative regulation of growth of symbiont in host GO:0044130 9.72 IL10 TNF
22 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.72 IL10 TNF
23 positive regulation of interleukin-12 production GO:0032735 9.72 IFNG TLR2 TLR4
24 pentose-phosphate shunt GO:0006098 9.71 G6PD PGD
25 regulation of cytokine secretion GO:0050707 9.71 TLR2 TLR4
26 I-kappaB phosphorylation GO:0007252 9.71 TLR2 TLR4
27 positive regulation of immunoglobulin secretion GO:0051024 9.71 GPI IL5
28 positive regulation of chemokine production GO:0032722 9.71 TLR2 TLR4 TNF
29 positive regulation of B cell proliferation GO:0030890 9.71 IL13 IL4 IL5 TLR4
30 positive regulation of podosome assembly GO:0071803 9.7 IL5 TNF
31 response to molecule of bacterial origin GO:0002237 9.7 IL10 TLR2
32 macrophage activation GO:0042116 9.7 SLC11A1 TLR4
33 microglial cell activation GO:0001774 9.7 IL13 TLR2 TNF
34 inflammatory response GO:0006954 9.7 IL10 IL13 IL5 SLC11A1 TLR2 TLR4
35 cellular response to lipoteichoic acid GO:0071223 9.69 TLR2 TLR4
36 glucose 6-phosphate metabolic process GO:0051156 9.69 G6PD GPI
37 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.69 TLR4 TNF
38 positive regulation of macrophage activation GO:0043032 9.69 IL10 IL13 TLR4
39 endothelial cell apoptotic process GO:0072577 9.68 IL10 TNF
40 negative regulation of cytokine secretion involved in immune response GO:0002740 9.67 IL10 TNF
41 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.67 FCER2 TLR2 TLR4
42 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.66 FCER2 TNF
43 positive regulation of killing of cells of other organism GO:0051712 9.65 FCER2 IFNG
44 negative regulation of interleukin-17 production GO:0032700 9.65 FOXP3 IFNG TLR4
45 regulation of isotype switching GO:0045191 9.64 IL10 IL4
46 type 2 immune response GO:0042092 9.64 IL10 IL4
47 negative regulation of complement-dependent cytotoxicity GO:1903660 9.63 IL13 IL4
48 pentose-phosphate shunt, oxidative branch GO:0009051 9.62 G6PD PGD
49 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.62 IFNG TNF
50 receptor biosynthetic process GO:0032800 9.61 IL10 TNF

Molecular functions related to Cutaneous Leishmaniasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.26 GPI IL10 IL4 IL5
2 cytokine activity GO:0005125 9.17 GPI IFNG IL10 IL13 IL4 IL5
3 lipopolysaccharide receptor activity GO:0001875 9.16 TLR2 TLR4

Sources for Cutaneous Leishmaniasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....